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Editorial Comment 
Platelet Activation in Unstable genie basis of myocardial &hernia (8) may be incorrect. 
Angina: Role of Thromboxane A, 
Furthermore, release of thromboxane A, in acute myocar- 
dial ischemia does not necessarily incriminate thromboxane 
And Other Mediators A, as the sole basis of myocardial ischemia; it may well be a consequence of the ischemic process. Nonetheless, throm- 
Of Vasoconstriction* boxane A,, even if released after platelet activation in the 
stenotic coronary artery, could participate in perpetuation of 
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Acute myocardial ischemia manifested by clinical syn- 
dromes of unstable angina and acute myocardial infarction 
usually is a result of an occlusive thrombus in an atheroscle- 
rotic coronary artery. A transient and intermittent reduction 
in coronary blood flow results in a brief period of ischemia 
from which the myocardium may recover, whereas a per- 
sistent and prolonged reduction may cause myocardial in- 
farction. In elegant pathologic studies, Falk (1) has shown 
that thrombosis in the atherosclerotic human coronary ar- 
tery is initiated by accumulation of platelets at the site of 
endothelial disruption. Activated platelets release potent 
spasmogens and platelet aggregants, such as thromboxane 
A, and serotonin, that exert a vasoconstrictive influence 
either at the site of thrombus or downstream, beyond the site 
of arterial occlusion. 
Role of arachidonic acid metabolites. Several investiga- 
tors (2-4) have documented release of arachidonic acid 
metabolite thromboxane A, in the coronary venous blood of 
patients with unstable angina and have implicated thrombox- 
ane A, in vasoconstriction and in vivo platelet aggregation. 
Early studies (5) also showed reduced formation of another 
arachidonate metabolite, prostacyclin, a potent vasodilator 
and platelet-inhibiting eicosanoid, in the atherosclerotic ar- 
teries. However, recent studies (6,7) show enhanced rather 
than reduced prostacyclin formation in atherosclerotic arter- 
ies. Therefore, the initial hypothesis of enhanced thrombox- 
ane A, and diminished prostacyclin formation as a patho- 
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the ischemic event. 
Platelet-vessel wall interaction. Platelets adhere to the 
vessel wall after the loss of endothelial continuity. In addi- 
tion to having a major role in hemostasis, platelets are 
critically important in the maintenance of endothelial integ- 
rity (9). Recent studies (10) have shown that coronary artery 
endothelium regulates platelet-vessel wall interactions. For 
example, aggregating platelets relax human coronary artery 
rings by inducing release of endothelium-derived relaxing 
factor (EDRF), but platelets constrict coronary smooth 
muscle when endothelium has been removed. The vasore- 
laxant effect of platelets is mediated by release of adenosine 
diphosphate (ADP), whereas the vasoconstrictor effect is 
expressed by the release of thromboxane A, and serotonin. 
In patients with coronary artery disease, clear evidence for 
diminished release of endothelium-derived relaxing factor, 
measured as coronary artery relaxation in response to ace- 
tylcholine, has now been documented by several investiga- 
tors (11-13). 
Potential role of leukocytes in myocardial &hernia. Circu- 
lating leukocytes, which appear in the platelet-rich thrombi 
as well as along the blood vessels in the ischemic myocar- 
dium, also play a role in the regulation of hemostasis and 
vascular tone. Although the contribution of leukocytes in 
reperfusion injury to the myocardium has been recently 
emphasized (14-16), leukocytes also exert prothrombotic as 
well as fibrinolytic effects. The superoxide and hydrogen 
peroxide radicals released from activated leukocytes can 
induce platelet aggregation and injure the vascular endothe- 
lium (17,18). Arachidonate metabolites in the leukocytes, or 
leukotrienes (C,, D, and E4), potentiate platelet aggregation 
and vasoconstriction (19,20). In conjunction with thrombox- 
ane A,, these peptido-leukotrienes exert a negative syner- 
gistic effect on blood flow in the stenotic coronary artery and 
induce regional myocardial dysfunction (21). Leukocytes 
also participate in fibrinolysis by nonplasmin-mediated 
mechanisms (22). Recent studies (23) have shown that neu- 
trophils also release a nonprostaglandin substance that re- 
laxes arterial smooth muscle and inhibits platelet aggrega- 
tion. The biologic characteristics of this substance suggest 
that the neutrophil-derived vasorelaxant is similar to the 
endothelium-derived relaxing factor. 
Cyclic reduction in flow in stenotic arteries. Since the first 
description of cyclic flow reductions in stenotic coronary 
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arteries of dogs by Uchida et al. (24), several investigators 
(25-30) have shown that these reductions in coronary blood 
flow are caused by periodic formation of platelet aggregates 
followed by their spontaneous dissolution. Measurements 
distal to the coronary occlusion site show release of large 
amounts of thromboxane A, metabolite, indicating platelet 
activation (26). Not unexpectedly, a variety of platelet-in- 
hibiting drugs that act by inhibiting the enzyme cyclooxy- 
genase, such as aspirin, indomethacin, ibuprofen and 
sulfinpyrazone, decrease or abolish the frequency of cyclic 
reductions in coronary blood flow (25). Incidentally, these 
drugs in the dosages used inhibit formation of both throm- 
boxane A, and prostacyclin. Aiken et al. (27) showed that 
the selective thromboxane A, inhibitor U63,557A abolishes 
the cyclic reductions in coronary blood flow, and they 
implied that the increased formation of prostacyclin proba- 
bly contributes to the salutary effects of U63,557A. Subse- 
quent studies (28,29) showed that other selective thrombox- 
ane A, synthetase inhibitors and thromboxane A, receptor 
antagonists also reduce or abolish these cyclic changes in 
coronary blood flow. These alterations in blood flow in the 
stenotic coronary artery are also markedly decreased by 
alpha,-adrenergic and serotonergic receptor antagonists 
(26). Golino et al. (30) demonstrated a greater efficacy of the 
combination of thromboxane A, receptor antagonists with 
serotonergic receptor antagonists than of either agent alone. 
These observations suggest that several vasoconstrictors are 
released during platelet aggregation in a stenotic coronary 
artery and that multiple mediators need to be blocked to 
abolish platelet aggregation-mediated events. The recent 
observations of Fitzgerald et al. (31) relative to the release of 
large amounts of thromboxane A, after thrombolysis incrim- 
inate ongoing platelet activation in the evolution of coronary 
reocclusion. In their studies in dogs, thromboxane A, recep- 
tor antagonists were effective in preventing rethrombosis; 
however, use of a monoclonal antibody against the platelet 
glycoprotein IIb/IIIa receptors also inhibited reocclusion, 
whereas thromboxane A, release was not affected. These 
observations suggest that platelet aggregation limits the 
response to coronary thrombolysis but that coronary artery 
occlusion is only partially thromboxane A, dependent. 
Vasospasm and reduction in coronary blood flow: the 
present study. Does vasospasm play a role in the genesis of 
acute myocardial ischemia when a thrombus is occluding the 
coronary artery? Folts et al. (25) demonstrated in dogs a 
reduction in the coronary lumen before total occlusion of a 
stenotic coronary artery by aggregating platelets, but nitro- 
glycerin failed to affect the cyclic reductions in blood flow. 
In this issue of the Journal, Golino et al. (32) in a similar 
canine model now confirm these observations of reduction in 
coronary lumen at the nadir of coronary blood flow. They 
also show that two potent spasmolytic agents, nitroglycerin 
and diltiazem, do not affect either the cyclic flow reductions 
or the associated reduction in coronary lumen. Thus, al- 
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though the occurrence of vasoconstriction in conjunction 
with intracoronary platelet aggregation may be an important 
consideration, it is not influenced by either nitroglycerin or 
diltiazem, both of which are weak platelet-inhibiting agents. 
These observations taken together do not suggest that va- 
sospasm is a critical step in the genesis of myocardial 
ischemia if we assume that most episodes of acute myocar- 
dial ischemia are related to the formation of an occlusive 
thrombus in the stenotic coronary artery. The reduction in 
coronary lumen may reflect a potent smooth muscle con- 
striction in response to release of multiple spasmogens from 
platelets and leukocytes when the protective influence of 
endothelium has been lost. 
Clinical relevance of experimental observations. Are the 
observations on platelet activation and thromboxane A, 
release made in the artificially stenosed coronary artery of 
dogs, in which no other rheologic or cellular abnormality 
exists, relevant in the clinical setting of unstable angina? 
Certainly infusion of prostacyclin, which abolishes platelet 
activation in a narrowed coronary artery of the dog, is not 
beneficial in patients with unstable angina. Actually, it 
appears to be detrimental despite its very potent platelet 
aggregation-inhibiting effects (33). Thromboxane A, syn- 
thetase or receptor antagonists also do not appear to be 
effective in patients with myocardial ischemia (34-36). In 
contrast, aspirin, which inhibits both thromboxane A2 and 
prostacyclin synthesis, is extremely effective in both pri- 
mary and secondary prevention of myocardial ischemia (37), 
whereas indomethacin, which inhibits arachidonate metab- 
olism at the same step as aspirin, has no beneficial effect. It 
is possible that the multiple actions of aspirin (reviewed in 
ref. 37) contribute to its efficacy. Coronary heart disease is a 
complex multifactorial disease whose pathologic basis 
evolves over decades of life span, although sudden alter- 
ations in rheology and platelet function precipitate acute 
myocardial ischemia. It is my opinion that platelet-vessel 
wall interactions are important from a pathophysiologic 
viewpoint in unstable angina and that thromboxane AZ 
represents only one of the several important mediators of 
platelet activation and vasoconstriction. As such, use of 
selective thromboxane A, inhibitors alone may not be ben- 
eficial. A multipronged therapy, including use of drugs that 
inhibit thromboxane A2 formation, such as aspirin, should 
continue to be employed, while the search continues for the 
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